A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study.

Burtness, B A

A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. [electronic resource] - Annals of oncology : official journal of the European Society for Medical Oncology May 2008 - 977-83 p. digital

Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural

1569-8041

10.1093/annonc/mdm591 doi


Adult
Aged
Antibiotics, Antineoplastic--administration & dosage
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Carcinoma, Squamous Cell--drug therapy
Combined Modality Therapy
Disease-Free Survival
Docetaxel
Drug Administration Schedule
Drug Resistance, Neoplasm
Epothilones--administration & dosage
Female
Head and Neck Neoplasms--drug therapy
Hematologic Diseases--chemically induced
Humans
Infusions, Intravenous
Male
Middle Aged
Paclitaxel--administration & dosage
Peripheral Nervous System Diseases--chemically induced
Recurrence
Salvage Therapy
Survival Analysis
Taxoids--administration & dosage